Puma Biotechnology Q4 Revenue Hits $75.5M on $59.9M NERLYNX Sales
Puma reported Q4 2025 total revenue of $75.5 million, driven by NERLYNX net sales of $59.9 million (up $8.0 million sequentially) and royalty revenue of $15.6 million. The company sold 3,298 NERLYNX bottles (up 349 sequentially), saw field call activity rise 23% year-over-year, and expects sequential recovery.
1. Financial Results
Puma posted Q4 2025 total revenue of $75.5 million, up sequentially on higher NERLYNX net sales of $59.9 million and royalty income of $15.6 million. GAAP net income reached $13.4 million ($0.20 per share) and non-GAAP net income was $15.1 million ($0.30 per share).
2. Commercial Performance
Sales of NERLYNX climbed to 3,298 bottles (up 349 from Q3), with U.S. net sales at $55.2 million and ex-U.S. product supply revenue at $4.7 million. Field call activity grew 23% year-over-year but fell 13% sequentially due to vacant territories, while specialty distribution demand rose 17% quarter-over-quarter.
3. Clinical Development
Enrollment in the Phase II ALISCA-Breast1 trial reached 164 patients ahead of the initial 150-patient target, with interim data expected in Q2 2026. In ALISCA-Lung1, dosing was increased to 60 mg BID following pharmacokinetic findings, 79 patients are enrolled, and a combination trial with paclitaxel is planned.